Association Between Circulating GDF‐15 and Cardio‐Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial

Association Between Circulating GDF‐15 and Cardio‐Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial

Background Studies have suggested that sodium glucose co‐transporter 2 inhibitors exert anti‐inflammatory effects. We examined the association of baseline growth differentiation factor‐15 (GDF‐15), a marker of inflammation and cellular injury, with cardiovascular events, hospitalization for heart fa...

Full description

Bibliographic Details
Main Authors: Taha Sen, Jingwei Li, Brendon L. Neuen, Clare Arnott, Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey, Wayne Shaw, William Canovatchel, Michael K. Hansen, Hiddo J. L. Heerspink
Format: Article
Language:English
Published: Wiley 2021-12-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
canagliflozin
GDF‐15
renal and cardiovascular outcomes
SGLT2 inhibitor
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.121.021661

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.121.021661

Similar Items